Using Health Technology Assessment to Inform Insurance Reimbursement of High Technology Medicines in China: an Example of Cancer Immunotherapy

Yingyao Chen,Hengjin Dong,Yan Wei,Yi Yang,Jian Ming,Hao Yu

DOI: https://doi.org/10.1136/bmj-2022-069963

2023-01-01

BMJ

Abstract:Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit

What problem does this paper attempt to address?

Use of Health Technology Assessment in Drug Reimbursement Decisions in China.

Wen Chen,Luying Zhang,Min Hu,Shanlian Hu

DOI: https://doi.org/10.1136/bmj-2021-068915

2023-01-01

BMJ

Abstract:China has made substantial progress in using health technology assessment, but more effort should be made to improve the quality of evidence, strengthen capacity, and enhance transparency, say Wen Chen and colleagues
Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?

Cong Huang,Carolina Oi Lam Ung,Haishaerjiang Wushouer,Lin Bai,Tao Huang,Xinyi Li,Xiaodong Guan,Luwen Shi

DOI: https://doi.org/10.1186/s12961-021-00810-1

2022-01-01

Health Research Policy and Systems

Abstract:Background In China, health technology assessment (HTA) has recently been adopted in pricing negotiation for medicine listing in the National Reimbursement Drug List. At present, how HTA is applied to inform the decision-making process remains underreported. In order to explore how the adoption of HTA was translated into listing and price negotiation results in light of the confidential nature of the negotiating process, this study aimed to compare the negotiated price and the clinical benefit of selected targeted anticancer medicines (TAMs) involved in the 2019 negotiation. Main text Among 16 TAMs successfully negotiated, only four TAMs representing four indication groups had appropriate reference medicines for comparison and were, therefore, included in the analysis. The price and clinical benefit of the four TAMs were compared against one or two reference medicines with the same initial indications. The sales prices for nine TAMs before and after the negotiation were extracted from the centralized medication procurement system. Clinical benefits were evaluated based on evidence from published articles and clinical guidelines. The results suggested that, despite the application of HTA, both rational and irrational decisions had been made about the reimbursement of TAMs in the 2019 negotiation, warranting further investigation. Conclusion While the development and adoption of HTA has seen significant progress in China, actions are needed to ensure that the adoption of HTA is effectively applied in decisions on the reimbursement of medicines.
Health Technology Assessment and Its Use in Drug Policies in China

X. Zhen,H. Dong

DOI: https://doi.org/10.1016/j.vhri.2018.01.010

IF: 5.156

2018-01-01

Value in Health

Abstract:ObjectiveTo review drug policies, health technology assessment (HTA), and HTA’s use in drug policies in China, to further improve the quality and efficiency of drugs.MethodsThis study draws on multiple methods. A systematic review of the literature, review of Chinese government documents and statistical handbooks, and authors’ experiences in drug policies and HTA in China were combined to achieve the objective.ResultsOf 571 studies identified in the initial search, 14 eligible articles (6 English, 8 Chinese) were finally included. On the Web site of the National Health and Family Planning Commission, the National Development and Reform Commission, and the Ministry of Human Resources and Social Security, we found that HTA or pharmacoeconomics evaluation is mentioned in recent years and its frequency has been increasing; however, there was not one hit about HTA or PE on the Web site of China Food and Drug Administration.ConclusionsThe decision makers have realized the importance and value of HTA and have tried to integrate HTA into drug policies and regulations. However, the application of HTA findings to drug policymaking is not yet widespread and there are a number of challenges in using HTA in China. Therefore, it is necessary to establish a national HTA commission and develop pharmacoeconomics guidelines to support the use of HTA in decision making. Moreover, the most important steps are to encourage technology innovation, groom more HTA experts, and build reliable databases in China.
Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study

Wenqing Fang,Xinglu Xu,Yulei Zhu,Huizhen Dai,Linlin Shang,Xin Li

DOI: https://doi.org/10.3389/fpubh.2021.714127

IF: 5.2

2021-08-06

Frontiers in Public Health

Abstract:Objective: The study aimed to evaluate the impact of the National Health Insurance Coverage (NHIC) policy on the utilisation and accessibility of innovative anti-cancer medicines in Nanjing, China. Methods: We used the adjusted World Health Organisation and Health Action International methodology to calculate the price and availability of 15 innovative anti-cancer medicines included in the National Health Insurance drug list in 20 tertiary hospitals and six secondary hospitals in Nanjing before and after NHIC policy implementation. Interrupted time-series regression was used to analyse the changes in the utilisation of the study medicines. Results: The price reduction rates of innovative anti-cancer medicines ranged between 34 and 65%. The mean availability rate was 27.44% before policy implementation and increased to 47.33% after policy implementation. The utilisation of anti-cancer medicines suddenly increased with a slope of 33.19–2,628.39 when the policy was implemented. Moreover, the usage rate of bevacizumab, bortezomib, and apatinib significantly increased ( p < 0.001, p = 0.009, and p < 0.001, respectively) after policy implementation. With regard to price reduction and medical insurance reimbursement, the medicines became more affordable after policy implementation (0.06–1.90 times the per capita annual disposable income for urban patients and 0.13–4.46 times the per capita annual disposable income for rural patients). Conclusion: The NHIC policy, which was released by the central government, effectively improved the utilisation and affordability of innovative anti-cancer medicines. However, the availability of innovative anti-cancer medicines in hospitals remained low and the utilisation of innovative anti-cancer medicines was affected by some factors, including the incidence of cancer, limitation of indications within the insurance program, and the rational use of innovative anti-cancer medicines. It is necessary to improve relevant supporting policies to promote the affordability of patients. The government should speed up the process of price negotiation to include more innovative anti-cancer medicines in the medical insurance coverage, consider including both medical examinations and adjuvant chemotherapy in the medical insurance, and increase investment in health care.

public, environmental & occupational health
Differences in reimbursement listing of anticancer therapies in China: an observational study

Xiaodong Guan,Yichen Zhang,Haishaerjiang Wushouer,Luwen Shi,Dennis Ross-Degnan,Anita Katharina Wagner

DOI: https://doi.org/10.1136/bmjopen-2019-031203

IF: 3.006

2020-01-01

BMJ Open

Abstract:Objective Access to highly priced anticancer medications usually requires insurance coverage. A first step towards coverage of such medications is their inclusion in reimbursement lists. We assessed listing for reimbursement in China between 2009 and 2018 of anticancer medications on the WHO's Essential Medicines List. Setting and study design Using publicly available data, we assessed which anticancer medications listed in the 20th WHO Model List of Essential Medicines (EML) were included in China's National Reimbursement Drug List (NRDL). For five targeted anticancer medications on the WHO EML, we also assessed inclusion in the 31 Chinese Provincial Reimbursement Drug Lists (PRDLs). Logistic regression was used to test whether inclusion of targeted anticancer medications was associated with provincial economic levels. Primary outcome measures Inclusion of five targeted anticancer medications in the NRDL and PRDLs before and after 2017. Results The 2017 NRDL included all anticancer medications on the WHO EML (except for one not approved in China at the time), and by 2018, all 31 PRDLs listed the targeted anticancer medications except for nilotinib; four provinces had covered all five targeted medications before the 2017 NRDL coverage mandate. Provincial economic level and regional incidence of specific cancers seemed unrelated to the inclusion of five targeted anticancer medications in PRDLs. Conclusion Our findings suggest that by including medications in the national and provincial reimbursement lists, China has taken an important first step in promoting access to targeted anticancer medications. Further research is needed to determine whether inclusion in PRDLs improved the availability, appropriate use and affordability of highly priced targeted anticancer medications in China.
How Government Insurance Coverage Changed the Utilization and Affordability of Expensive Targeted Anti-Cancer Medicines in China: an Interrupted Time-Series Study

Yifan Diao,Jie Qian,Yang Liu,Yanping Zhou,Yan Wang,Hong Ma,Xiaoyan Wang,Ren Luo,Anita Wagner,Jing Sun,Yuanli Liu

DOI: https://doi.org/10.7189/jogh.09.020603

2019-01-01

Journal of Global Health

Abstract:Methods Using an interrupted time series design, we conducted segmented regression analyses of utilization changes of targeted anti-cancer medicines covered by the provincial government health insurance program during 2013 to 2016 in 69 hospitals with more than 100 beds in Hangzhou, the capital city of Zhejiang province of China. The WHO/Health Action International Project on Medicine Prices and Availability methodology was used to measure patient affordability of the study medicines. Results In March 2015, the utilization of all study medicines increased by 15.58 (95% CI = 3.86, 27.30, P = 0.01) to 439.14 standard units (95% CI = 311.79, 566.49, P < 0.001). Before covered by government health insurance, the estimated out-of-pocket payment by patient ranged from 3.0 to 13.1 times of the provincial average disposable annual income per capita for urban residents, and 6.2 to 27.3 times for rural residents. Such payments were reduced to 0.6 to 2.1 times for urban residents and 1.8 to 4.4 times for rural population after government health insurance coverage inclusion. During 2015 to 2016, the per capita contribution to Hangzhou catastrophic health insurance program was CNY15 (US$ 2.3), and the reimbursement rate was 70% in Hangzhou city. The cumulative total insurance expenses on six study targeted anticancer medicines accounted for an estimated 53% of the total amount of premiums of the government catastrophic health insurance fund. Sensitivity analyses indicated that this proportion would have changed to 46%, 61% and 69% when changing the per capita contribution to CNY25 (US$ 3.8) and CNY40 (US$ 6.2), and changing the insurance reimbursement rate to 60%, 80 and 90%. Conclusion Government health insurance coverage inclusion significantly increased utilization of the expensive targeted anti-cancer medicines, and improved patient affordability. However, the financial burden of patients is still high, especially for the rural low-income population. Rising utilization and expenditures call for careful monitoring of anti-cancer medicines use, and for strategies to decrease prices to facilitate medicines access and keep the insurance system sustainable.
The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data

Yu Yang,Yichen Zhang,Anita K Wagner,Huangqianyu Li,Luwen Shi,Xiaodong Guan

DOI: https://doi.org/10.7189/jogh.13.04083

2023-08-11

Journal of Global Health

Abstract:Background: High prices of targeted anticancer medicines (TAMs) result in financial toxicity for patients and the health insurance system. How national price negotiation and reimbursement policy affect the accessibility of TAMs for cancer patients remains unknown.Methods: In this population-based cohort study, we used national health insurance claims data in 2017 and identified adult patients with cancer diagnoses for which price-negotiated TAMs were indicated. We estimated the half-month prevalence of price-negotiated TAMs use before and after the policy implementation in September 2017. We calculated direct medical costs, out-of-pocket (OOP) costs, and the proportion of OOP cost for each cancer patient to measure their financial burden attributable to TAMs use. We performed segmented linear and multivariable logistic regression to analyse the policy impact.Results: We included 39 391 of a total 118 655 cancer beneficiaries. After September 2017, the prevalence of price-negotiated TAMs use increased from 1.4%-2.1% to 2.9%-3.1% (P = 0.005); TAMs users' daily medical costs increased from US$261.3 to US$292.5 (P < 0.001), while median daily OOP costs (US$68.2 vs US$65.7; P = 0.134) and OOP costs as a proportion of daily medical costs persisted (28.5% vs 28.5%; P = 0.995). Compared with resident beneficiaries, the relative probability of urban employee beneficiaries on TAMs uses decreased after the policy (adjusted odds ratio (aOR) = 2.4 vs aOR = 2.2).Conclusions: The government price negotiation and reimbursement policy improved patient access to TAMs and narrowed disparities among insurance schemes. China's approach to promoting the affordability of expensive medicines provides valuable experience for health policy decision-makers.

public, environmental & occupational health
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China

Yichen Zhang,Haishaerjiang Wushouer,Sheng Han,Mengyuan Fu,Xiaodong Guan,Luwen Shi,Anita Wagner

DOI: https://doi.org/10.1136/bmjgh-2021-006196

IF: 8.056

2021-07-01

BMJ Global Health

Abstract:Introduction New targeted therapies have changed cancer treatment in the past decades. However, high prices of targeted anticancer medications have increased economic burden for both patients and health insurance systems. In July 2017, China implemented combined medication price negotiation and mandatory reimbursement policies for 15 targeted anticancer medications. This study assesses effects of the policy on hospital procurement prices, volumes and spending. Methods Using a quasi-experimental interrupted time series design, we analysed procurement data from the Chinese Medical Economic Information of 789 public hospitals in 30 provinces between January 2016 and September 2018. The intervention group consisted of 15 targeted anticancer medications with negotiated prices in 2017. The comparison group consisted of six targeted anticancer medications without negotiated prices by 2018. The effective date of the policy was September 2017. Results After the implementation of the 2017 medication price negotiation and reimbursement policy, cost per defined daily dose (DDD) of the 15 targeted anticancer medications dropped US$71.21 on average from an average US$169.24/DDD before (p=0.000). Compared with what would have happened without the intervention, cost/DDD of price-negotiated medications decreased by 48.9% (p=0.000), procurement volumes increased by 143.0% (p=0.000) and hospital medication spending decreased by 6.9% (p=0.146). Conclusions The 2017 medication price negotiation and reimbursement policy decreased targeted medication procurement costs per DDD, increased volumes procured and at least temporarily contained spending. These changes should result in better access to and affordability of targeted anticancer medications in China.

public, environmental & occupational health
Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China

Xia Mingge,Wen Jingyu,Liu Qi,Zheng Zhe,Ran Qing

DOI: https://doi.org/10.1177/00469580231170729

2023-01-01

Abstract:Providing universal access to high-cost medications like anticancer drugs is not an easy feat. Although basic medical insurance has covered over 95% of China’s population since 2012, reimbursement for high-priced medicines is limited. In 2015, the Chinese government proposed establishing an open and transparent price negotiation mechanism for some patented and expensive drugs, where oncology was among the prioritized areas. In 2016, three drugs (gefitinib, icotinib, and tenofovir disoprox) underwent negotiation with the government, eventually reducing their prices by over 50% so that they could be prioritized during reimbursement processes. Focusing on anticancer medicines, this study comprehensively summarizes the progress in drug price and national reimbursement negotiation in China. Furthermore, we investigated the changes and development regarding negotiated anticancer medicines from quantity negotiated, classification, indication coverage, utilization, and procurement spending. Our findings could provide a reference for follow-up negotiations and reimbursement policies for high-value anticancer medications in other countries. From 2016 to 2021, 82 anticancer medicines were newly incorporated into the national reimbursement drug list (NRDL) via 6 rounds of negotiation. The majority of these were innovative pharmaceutics (ie, protein kinase inhibitors (28) and monoclonal antibodies (13)). Drug pricing and national reimbursement negotiation led to a marked decrease in prices and a sharp increase in the utilization of negotiated anticancer medicines. Following negotiations, the defined daily doses (DDDs) of innovative anticancer medicines experienced remarkable growth. Their proportion in total anticancer drugs DDDs also increased from 3.4% in 2014 to 20.9% in 2019. However, although drug prices decreased substantially after the negotiations, insurance spending still showed an upward trend owing to the significant increase in utilization. This calls for the government to carefully monitor the rational use of these expensive medicines and explore innovative payment models.

health care sciences & services,health policy & services
Introduction to knowledge translation from health technology assessment to health policy in China

CHEN Ying-yao,TANG Meng,MAO Yi-wei,SHI Li-zheng,DONG Heng-jin

DOI: https://doi.org/10.3969/j.issn.1674-2982.2013.07.001

2013-01-01

Abstract:Health technology assessment is recognized internationally and is increasingly important in health policy-making. This paper discusses the stakeholders in health technology,reviews the international experience on knowledge translation from health technology assessment to health policy,and proposes a conceptual model of the potential influencing factors. After reviewing the current situation of knowledge translation in China,this paper has also proposed some research ideas for further studies,such as a measurement on the extent of knowledge translation from health technology assessment to health policy,an identification of the influencing factors during the knowledge translation process and the extent to which they influence knowledge translation.
Health technology assessments and health policies on hip replacement in China: Whether or not research informs policy-making

TANG Meng,CHEN Ying-yao,MAO Yi-wei,SHI Lizheng,DONG Heng-jin

DOI: https://doi.org/10.3969/j.issn.1674-2982.2013.07.004

2013-01-01

Abstract:Objective: This paper is to explore the correspondence between health technology assessments and policies on hip replacements in China by comparing research on hip replacements with policies issued by the Ministry of Health. Methods: This study retrieved systematic reviews and meta-analyses on hip replacements from 1975 to 2012 and collected Ministry of Health policies on hip replacements,and analyzed these policies in light of the research done. Results: The Ministry of Health released its first policy on hip replacements in 2005 for approving hip replacement applications. However,the influence of health technology assessments in this policy was not evident. In 2009,two policies related to single-disease quality control were released,and there is evidence that these policies were partly informed by meta-analysis of hip replacements. The latest policies on hip replacements were released in 2012. These policies reflect meta-analyses published between 2009 and 2012. Conclusions: Although it has not always been the case,health technology assessments-including systematic reviews and meta-analyses-are now being considered by the Ministry of Health when they formulate national policies on hip replacements.
Evaluation of Targeted Anticancer Agents Incorporated into Medical Insurance Policy: Taking a Tertiary Oncology Institution in Beijing as an Example

陈治水,冷家骅,高广颖,刘忆

DOI: https://doi.org/10.7664/CHE20181007

2018-01-01

Abstract:Objective: To evaluate changes in cost indicators of medical institution before and after the reimbursement policy of targeted drugs incorporated into the medical insurance, and provide data support for the continued advancement of medical insurance payment reform. Methods: Retrospectively by collecting monthly data of hospitalized patients before and after the targeted agents’ reimbursement policy in a cancer hospital of Beijing, and using interrupted time series analysis to explore the immediate effects and long-term trends after the reform. Results: After the reform, the number of daily outpatient visits rose by 20.04 per month; the outpatient and inpatient per capita costs changed by 33.44 yuan and 468.75 yuan respectively, the outpatient and inpatient proportion of drugs increased by 1.80% and 1.89% respectively; the proportion of outpatient auxiliary drug use had a long-term decline trend of 0.61%; the ratio at patients’ own expense fell immediately, and the actual compensation rate increased as well. Conclusion: After the implementation of target agents incorporated into medical insurance reimbursement policy, the individual burden of the patients could be controlled while the rational use of clinical medicine could be improved, however, it would bring the dual control pressure of the fund and the ratio of the medicine, so the top design should be integrated.
The application of health technology assessment in Australia

Yi-wei MAO,Ying-yao CHEN,Meng TANG,Wen-bin LIU

DOI: https://doi.org/10.3969/j.issn.1007-953X.2014.06.037

2014-01-01

Abstract:The implementation of health technology assessment in Australia is one of the world’s successful experiences. Health technology assessment in Australia began from pharmaceutical benefit schedule and developed as time went on. Now health technology assessment is applied into more areas,and the whole process is about 20 years. The success has common in characteristics of other countries,however,it has unique characteristic at the same time, and there still exists space for improvement,which also hints that the development of health technology assessment in China needs to learn from international successful experiences and make it localized.
Development of Health Technology Assessment in China: New Challenges

Yingyao Chen,Yao He,Xunyouzhi Chi,Yan Wei,Lizheng Shi

DOI: https://doi.org/10.5582/bst.2018.01038

2018-01-01

BioScience Trends

Abstract:Health technology assessment (HTA) is a field of scientific policy research that adopts multidisciplinary approaches to conduct systematic evaluation of health technologies and inform decision making. Although achievements have been made by HTA activities among academics, providers, and policy makers, development of the field of HTA in China is fragmented and not yet formally integrated in health policy making processes. All stakeholders need to make more efforts to strengthen HTA knowledge translation and facilitate a decision making process that is based on evidence including HTA findings. This article reviews how the field of HTA has developed in China, analyzes what factors have been influencing China's HTA development, and proposes policy recommendations.
Price negotiation and pricing of anticancer drugs in China: An observational study

Jing Zhou,Tianjiao Lan,Hao Lu,Jay Pan

DOI: https://doi.org/10.1371/journal.pmed.1004332

2024-01-02

PLoS Medicine

Abstract:Background While China has implemented reimbursement-linked drug price negotiation annually since 2017, emphasizing value-based pricing to achieve a value-based strategic purchase of medical insurance, whether drug prices became better aligned with clinical value after price negotiation has not been sufficiently established. This study aimed to assess the changes in prices and their relationship with the clinical value of anticancer drugs after the implementation of price negotiations in China. Methods and findings In this observational study, anticancer drug indications that were negotiated successfully between 2017 and 2022 were identified through National Reimbursement Drug Lists (NRDL) of China. We excluded extensions of indications for drugs already listed in the NRDL, indications for pediatric use, and indications lacking corresponding clinical trials. We identified pivotal clinical trials for included indications by consulting review reports or drug labels issued by the Center for Drug Evaluation, National Medical Products Administration. We calculated treatment costs as outcome measures based on publicly available prices and collected data on clinical value including safety, survival, quality of life, and overall response rate (ORR) from publications of pivotal clinical trials. The associations between drug costs and clinical value, both before and after negotiation, were analyzed using regression analyses. We also examined whether price negotiation has led to a reduction in the variation of treatment costs for a given value. We included 103 anticancer drug indications, primarily for the treatment of blood cancer, lung cancer, and breast cancer, with 76 supported by randomized controlled trials and 27 supported by single-arm clinical trials. The median treatment costs over the entire sample have been reduced from US$34,460.72 (interquartile range (IQR): 19,990.49 to 55,441.66) to US$13,688.79 (IQR: 7,746.97 to 21,750.97) after price negotiation ( P < 0.001). Before price negotiation, each additional month of survival gained was associated with an increase in treatment costs of 3.4% (95% confidence interval (CI) [2.1, 4.8], P < 0.001) for indications supported by randomized controlled trials, and a 10% increase in ORR was associated with a 6.0% (95% CI [1.6, 10.3], P = 0.009) increase in treatment costs for indications supported by single-arm clinical trials. After price negotiation, the associations between costs and clinical value may not have changed significantly, but the variation of drug costs for a given value was reduced. Study limitations include the lack of transparency in official data, missing data on clinical value, and a limited sample size. Conclusions In this study, we found that the implementation of price negotiation in China has led to drug pricing better aligned with clinical value for anticancer drugs even after substantial price reductions. The achievements made in China could shed light on the price regulation in other countries, particularly those with limited resources and increasing drug expenditures.

medicine, general & internal
Impact of competition on reimbursement decisions for cancer drugs in China: an observational study

Haijing Guan,Yin Shi,Jiafang Song,Mingnan Cao,Aning Sun,Shao Liu,Shi Chang,Zhigang Zhao

DOI: https://doi.org/10.1016/j.lanwpc.2024.101157

2024-07-25

Abstract:Background: Annual Chinese National negotiations for including innovative drugs in the National Reimbursement Drug List (NRDL) reveal an increasing number of new drugs with overlapping action mechanisms of action and similar indications. Yet, it is unclear if competition affects reimbursement decisions. Thus, we explored the impact of competition on reimbursement decisions for cancer drugs in China. Methods: We identified the cancer drugs involved in NRDL negotiations from 2017 to 2022 and focused on the initial reimbursement decision for eligible newly negotiated drugs. Drugs were classified as within-class competitors based on their equivalent biological mechanisms of action and approved indications, including identified and potential competitors. Other variables included drug type, clinical benefit and safety, monthly drug cost, and disease incidence rate. We employed traditional univariate and multivariate Firth's penalized logistic regression to assess the association between reimbursement decisions and variables at the indication and drug levels. Findings: Between 2017 and 2022, 102 cancer drugs corresponding to 141 indications were studied, and 66 drugs (64.7%) covering 95 indications (67.4%) were added to the NRDL. The proportion of reimbursements for indications with identified competition was significantly higher than that for indications without identified competition (84.6% vs 52.6%, p < 0.0001). However, the difference in reimbursement proportions between groups with and without potential competition was not statistically significant (66.7% vs 68.3%, p = 0.84). Firth's penalized logistic regression showed that identified competition was positively correlated with successful NRDL inclusion, whereas potential competition had no significant effect on negotiation outcomes. Improved overall survival or progression-free survival were positively associated with NRDL inclusion, whereas disease incidence negatively impacted reimbursement decisions. Interpretation: Improved clinical benefit and identified competition were positively correlated with NRDL inclusion. In China's value-based negotiation model, clinical benefits served as a crucial foundation of price negotiation for cancer drugs, and market competition helped these drugs enter the NRDL at more reasonable prices. This has important implications for reimbursement decisions and accessibility and affordability improvement for innovative drugs worldwide. Funding: National Natural Science Foundation of China (No. 72104151).
Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China

Zhaoliu Cao,Lili Wang,Rui Ma,Yun Hu,Baiyi Bao,Xiaohua Liu,Mengyuan Li,Xiao Wang,Pingyu Liu,Xin Li

DOI: https://doi.org/10.1186/s12913-024-11285-5

2024-07-13

BMC Health Services Research

Abstract:To evaluate the availability, cost, affordability of anti-cancer medicines in Nanjing, Jiangsu. A longitudinal tracking investigation study was performed to collect information about 24 essential anti-cancer medicines (EAMs) and 17 innovative anti-cancer medicines (IAMs) in 26 healthcare institutions in Nanjing from 2016 to 2020. The availability, cost, drug utilization and affordability of EAMs and IAMs were investigated.

health care sciences & services
Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis

Yanyan Liu,Huining Yi,Kexin Fang,Yuwen Bao,Xin Li

DOI: https://doi.org/10.3389/fpubh.2022.942638

2022-07-22

Abstract:Background: In order to establish a long-term strategy for bearing the costs of anti-cancer drugs, the state had organized five rounds of national-level pricing negotiations and introduced the National Health Insurance Coverage (NHIC) policy since 2016. In addition, the National Healthcare Security Administration (NHSA) introduced the volume-based purchasing (VBP) pilot program to Nanjing in September 2019. Taking non-small cell lung cancer as an example, the aim of the study was to verify whether national pricing negotiations, the NHIC policy and the VBP pilot program had a positive impact on the accessibility of three targeted anti-cancer drugs. Methods: Based on the hospital procurement data, interrupted time series (ITS) design was used to analyze the effect of the health policy on the accessibility and affordability of gefitinib, bevacizumab and recombinant human endostatin from January 2013 to December 2020 in Nanjing, China. Results: The DDDs of the three drugs increased significantly after the policy implementation (P < 0.001, P < 0.001, P = 0.008). The trend of DDDc showed a significant decrease (P < 0.001, P < 0.001, P < 0.001). The mean availability of these drugs before the national pricing negotiation was <30% in the surveyed hospitals, and increased significantly to 60.33% after 2020 (P < 0.001, P = 0.001, P < 0.001). The affordability of these drugs has also increased every year after the implementation of the insurance coverage policy. The financial burden is higher for the rural patients compared with the urban patients, although the gap is narrowing. Conclusion: The accessibility of targeted anti-cancer drugs has increased significantly after the implementation of centralized prices, the NHIC policy and the VBP pilot program, and has shown sustained long-term growth. Multi-pronged supplementary measures and policy approaches by multiple stakeholders will facilitate equitable access to effective and affordable anti-cancer drugs.
Health Technology Assessment Development In China

Yingyao Chen,David Banta,Zhiliu Tang

DOI: https://doi.org/10.1017/S0266462309090643

2009-01-01

International Journal of Technology Assessment in Health Care

Abstract:Objectives: This study is to review health technology assessment (HTA) development in China during the past two decades, and to facilitate further development of HTA and its integration into policy making.Methods: The study depends very much on the extensive experiences of the authors in involvement of HTA in China. In addition, literature review and Web site searching have been used to trace the process of growth of HTA in China.Results: With its rapid economic development, the Chinese health system has had many achievements in the past 30 years. However, there are some weaknesses that have developed during this period. HTA is traced back to the early 1990s in China. First, HTA knowledge transfer and establishment of HTA units were effective ways to develop HTA in China. By the end of 1990s, the policy makers of the Ministry of Health (MoH) made efforts to merge HTA with policy making to improve the quality and efficiency of health care. The main government authorities related to health technology are the State Food and Drug Administration, the Ministry of Labor and Social Security, and the MoH. Their involvements in HTA are varied.Conclusion: A technology licensure mechanism based on HTA, including technology permission for use, institution licensure, and workforce licensure, is being gradually carried out by the MoH in China. Moreover, HTA can play an important role in technology market entry, insurance benefit coverage, formulary, clinical pathway, reimbursement, and so on. There is a great opportunity for HTA to be an important part of health reform, especially to help policy makers within the health sector to make difficult decisions.
Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey

Gordon G Liu,Haijing Guan,Nan Peng,Shitong Xie,Kang Wang,Larry Z Liu,Yanbing Zhou,Huajie Jin

DOI: https://doi.org/10.1016/j.jval.2024.06.020

Abstract:Objectives: Health technology assessment (HTA) is increasingly crucial in medicine price negotiations in China, yet previous appraisals revealed national discrepancies on key economic evaluation issues: willingness-to-pay threshold, pricing models for multi-indication medicines, and comparator selection principles. This study aimed to collect expert opinions on these issues for future HTA evaluations. Methods: A nationwide anonymous web-based survey encompassing experts across academia, HTA, consultancy/contract research organization/industry, service provider, and payer. In 2023, a generic invitation containing a web link to the questionnaire was disseminated via WeChat using convenience and snowball sampling. Agreement rates for questionnaire views were analyzed using descriptive statistics. The relationship between participants' responses and demographics was examined using appropriate logistic models. Results: A total of 303 responses were received from experts in 34 cities. Key expert views include a suggested base willingness-to-pay threshold ranging from 0.5 to 1.5 times gross domestic product (52.1% agreement); elevated thresholds for childhood diseases, rare diseases, end-of-life diseases, and first-in-class medicines (>78.0% agreement); a single pricing model for multi-indication medicines (60.4% agreement); consideration of multiple medicines as comparators (79.9% agreement); and avoiding the use of centrally procured medicines as comparators for medicines with a time to market of less than 3 years (71.0% agreement). Participants who are service provider had lower odds of selecting higher thresholds (odds ratio 0.26; P < .01) than responders from consultancy/contract research organization/industry. Conclusions: Expert views indicate the need for substantial changes in China's current HTA methods, highlighting the need for increased investment in HTA processes and expertise cultivation.

Using Health Technology Assessment to Inform Insurance Reimbursement of High Technology Medicines in China: an Example of Cancer Immunotherapy

Use of Health Technology Assessment in Drug Reimbursement Decisions in China.

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?

Health Technology Assessment and Its Use in Drug Policies in China

Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study

Differences in reimbursement listing of anticancer therapies in China: an observational study

How Government Insurance Coverage Changed the Utilization and Affordability of Expensive Targeted Anti-Cancer Medicines in China: an Interrupted Time-Series Study

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China

Introduction to knowledge translation from health technology assessment to health policy in China

Health technology assessments and health policies on hip replacement in China: Whether or not research informs policy-making

Evaluation of Targeted Anticancer Agents Incorporated into Medical Insurance Policy: Taking a Tertiary Oncology Institution in Beijing as an Example

The application of health technology assessment in Australia

Development of Health Technology Assessment in China: New Challenges

Price negotiation and pricing of anticancer drugs in China: An observational study

Impact of competition on reimbursement decisions for cancer drugs in China: an observational study

Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China

Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis

Health Technology Assessment Development In China

Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey